In recent cancer therapy advances, tumor angiogenesis became a target, whereby a range of angiogenic factors, such as vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF), are inhibited [60]. The gene discussed is EGF; the disease is cancer.